ArticleFrontiers in oncology2026
Real world genomic profiling in non-small cell lung cancer reveals regional variations with clinical implications.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Routine targeted genomic profiling in non-small cell lung cancer (NSCLC) is primarily used to identify actionable alterations but may provide more information for clinical decision making. In this study routine genomic profiling data were used to examine the mutational landscape of lung cancer and its relationship to patient characteristics. Materials and methods: We analyzed Archer VariantPlex 67-gene sequencing data from 528 patients diagnosed with lung cancer in the North Swedish Health Care Region between 2011 and 2021 and linked the genomic results to registry-derived clinical and demographic data. Mutation frequencies, positional architectures, subgroup enrichments, and survival associations were compared within the regional cohort and against an external reference cohort assembled from cBioPortal. Results: After quality filtering, 1,415 somatic variants across 60 genes were identified, with a mean of 2.68 mutations per tumor, indicating substantial heterogeneity in mutational profiles. TP53 and KRAS formed a conserved mutational backbone across cohorts, whereas EGFR was less frequent and MET, APC, ATM, and CDKN2A were enriched in North Sweden relative to the external reference cohort. Major hotspot architectures were broadly preserved, although MET showed the clearest positional divergence. Mutation patterns varied by age, sex, smoking status, and disease stage. EGFR defined the most coherent clinical subtype, being enriched in females, never-smokers, younger patients, and earlier-stage disease, whereas KRAS, STK11, and TP53 were associated with smoking. EGFR was the strongest favorable prognostic marker, but stage strongly influenced the interpretation of many survival differences, indicating that gene-level prognostic signals are closely shaped by clinical context. Conclusions: Routine genomic profiling in NSCLC provides clinically relevant information beyond actionable driver detection when interpreted together with stage, smoking history, age, sex, and regional molecular context. These findings support a more context-aware interpretation of routine molecular diagnostics in thoracic oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.